Scrip
Dynavax exercises Symphony option for cash to fund Heplisav
11 November 2009
Sukaina Virji
Please Login to read the full article.
11 November 2009
Sukaina Virji
sukaina.virji@informa.com
Dynavax Technologies is exercising its option to purchase Symphony Dynamo (SDI), reaping $20 million in cash and rights to hepatitis C and cancer therapy programmes that were licensed from Dynavax.
SDI was set up in 2006 with
Symphony Capital, a private equity fund, providing $50 million...
Please Login to read the full article.
RELATED CONTENT
COMMENT
Other Informa Comment
FEATURES
- Cellectis: Partner search is on for meganuclease technology
- Face-to-Face: Trophos - The French firm that hooked Actelion
EVENTS
01 January 1970
London, UK
01 January 1970
San Diego, US
01 January 1970
Providence, Rhode Island, and San Francisco, California
JOB OF THE WEEK
Promote your vacancy here
